{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:22:55Z","timestamp":1787797375213,"version":"build-2784847793"},"reference-count":55,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study evaluated rates of treatment\u2010emergent resistance\u2010associated mutations (TE\u2010RAMs) and discontinuation due to adverse events (DC\u2010AEs) across integrase strand transfer inhibitor (INSTI)\u2010based single\u2010tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was conducted for phase 2\u20134 randomized controlled trials with \u226548\u2009weeks of follow\u2010up involving virologically suppressed people with HIV aged \u226512\u2009years and published January 2003\u2013March 2024. A random\u2010effects network meta\u2010analysis estimated comparative rates of TE\u2010RAMs and DC\u2010AEs among regimens at 48\u2009weeks. Risk of bias and strength of evidence were assessed using Cochrane RoB and CINeMA, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen (7509 participants) and nine (4656 participants) studies were included in the TE\u2010RAMs and DC\u2010AEs analyses, respectively. No significant differences in rates of TE\u2010RAMs were observed; risk ratios (RRs) for TE\u2010RAMs for bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF), dolutegravir\/abacavir\/lamivudine (DTG\/ABC\/3TC) and CAB + RPV every 4\u2009weeks (Q4W) versus CAB + RPV every 8\u2009weeks (Q8W) were 0.22 (95% CI, 0.02\u20132.04), 0.22 (95% CI, 0.00\u201319.85) and 0.40 (95% CI, 0.14\u20131.09). Compared with CAB + RPV Q4W and Q8W, DC\u2010AEs were significantly lower with B\/F\/TAF (RR, 0.15 [95% CI, 0.03\u20130.75] and RR, 0.16 [95% CI, 0.04\u20130.67], respectively) and DTG\/ABC\/3TC (RR, 0.05 [95% CI, 0.01\u20130.48] and RR, 0.05 [95% CI, 0.01\u20130.46], respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In virologically suppressed people with HIV, switching to CAB + RPV Q8W yielded a non\u2010significant increased risk of TE\u2010RAMs compared with INSTI\u2010based 2\u2010 and 3\u2010drug regimens and CAB + RPV Q4W. Both CAB + RPV Q4W and Q8W had significantly higher risks of DC\u2010AEs than B\/F\/TAF and DTG\/ABC\/3TC. Findings highlight the importance of considering both resistance and tolerability when switching regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70050","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:43:56Z","timestamp":1748393036000},"page":"1184-1198","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of treatment\u2010emergent resistance\u2010associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor\u2010based single\u2010tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with\n                    <scp>HIV<\/scp>\n                    : A systematic literature review and network meta\u2010analysis"],"prefix":"10.1111","volume":"26","author":[{"given":"Ishfaq","family":"Rashid","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy University of Utah College of Pharmacy  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan R.","family":"Unger","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Willis","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy University of Utah College of Pharmacy  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-6476","authenticated-orcid":false,"given":"Teerapon","family":"Dhippayom","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy University of Utah College of Pharmacy  Salt Lake City Utah USA"},{"name":"The Research Unit of Evidence Synthesis (TRUES) Faculty of Pharmaceutical Sciences, Naresuan University  Phitsanulok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Specialty Care Center  Fort Pierce Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-0684","authenticated-orcid":false,"given":"Elizabeth M.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Barry and Judy Silverman College of Pharmacy, Nova Southeastern University  Fort Lauderdale Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Yared","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases Henry Ford Health  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Safran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine MultiCare Health System INW  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Swiatlo","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases Southeast Louisiana Veterans Health Care System  New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soodi","family":"Navadeh","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard Weston","family":"Schmutz","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy University of Utah College of Pharmacy  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-8794","authenticated-orcid":false,"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy University of Utah College of Pharmacy  Salt Lake City Utah USA"},{"name":"Informatics, Decision\u2010Enhancement, and Analytic Sciences (IDEAS) Center Veterans Affairs Salt Lake City Healthcare System  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed October 17 2024.https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae016"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.09.009"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/v3040347"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/13596535231201162"},{"key":"e_1_2_9_14_1","unstructured":"World Health Organization.HIV drug resistance report 2017. Accessed September 17 2024.https:\/\/www.who.int\/publications\/i\/item\/9789241512831"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2196\/46767"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003085"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002466"},{"key":"e_1_2_9_18_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Higgins JPT","year":"2024"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074495"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075212"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12817"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8166"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70782-0"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001663"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002137"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70796-0"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00292-8"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae560"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae631"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf019"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac036"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy505"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1214"},{"issue":"7","key":"e_1_2_9_47_1","article-title":"P036. Long\u2010term follow\u2010up after a switch to bictegravir, emtricitabine, tenofovir alafenamide, from a boosted protease inhibitor\u2010based regimen","volume":"23","author":"Rockstroh J","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00185-5"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00184-3"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002883"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-20"},{"key":"e_1_2_9_52_1","unstructured":"WhiteK Niedziela\u2010MajkaA NovikovN et al.Bictegravir dissociation half\u2010life from HIV\u20101 G140S\/Q148H integrase\u2010DNA complexes. Presented at 24th Conference on Retroviruses and Opportunistic Infections (CROI); February 13\u201316 2017; Seattle WA USA. Poster 497."},{"key":"e_1_2_9_53_1","unstructured":"DudasK DeAndaF WangR et al.Characterization of NNRTI & INI resistance mutations observed in a study subject on oral two\u2010drug maintenance therapy with 10 mg cabotegravir + 25 mg rilpivirine. Presented at The XXIV International HIV Drug Resistance Workshop; February 21\u201022 2015; Seattle WA USA. Poster 13."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00157-11"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_2_9_56_1","unstructured":"FichtenbaumCJ MalvestuttoCD WatanabeMG et al.Abacavir Is Associated with Elevated Risk for Cardiovascular Events in the REPRIEVE Trial. Presented at: 25th International AIDS Conference; July 22\u201326 2024; Munich Germany. Oral OAB3406LB 2024."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:27:29Z","timestamp":1772958449000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/hiv.70050"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70050","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"2025-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}